Loading...
Symbols:
Authors:

The Genentech Guessing Game - What Will Roche Offer Next?

by: Mike Huckman August 21, 2008 | about stocks: DNA / RHHBY.PK    

Mike Huckman

About this author:
Become a Contributor Submit an Article
  • Font Size:
  • Print

Shares of Genentech (DNA) are taking another little breather after rising to around 99 bucks on speculation that a higher offer is coming from Roche (RHHBY.PK).

Analyst guesstimates of the ultimate takeout price -- if, indeed there is one -- are generally above a hundred dollars a share.

And the guy who recently suggested that $130 isn't out of the question is changing his odds today of a deal getting done.

Geoffrey Porges at Sanford C. Bernstein, who had been lamenting the potential loss of the Genentech culture and machine since Roche made its surprise bid, is now telling clients in a research note that an "acquisition seems inevitable."

He cites the recent statement from the special Genentech board committee, which Porges says "suggests that the company is resigned to a transaction..."

As a result, he's raising his DNA price target from $101 to $109.

But don't expect a deal to get done overnight: Porges thinks there will be at least one or two more negotiating rounds before they come to terms somewhere in the range of $105-$115 a share.

Finally, he now ascribes a less than 15 percent chance of the whole thing falling apart. But if that happens, look out below.

A unit of Bernstein owns at least 1 percent of DNA.

Related Articles

This article has 3 comments:

  •  
    Aug 21 06:52 PM
    What a shame if a deal does get done. Roche is just like Pfizer...unable to develop new novel med's themselves, they poach great companies.
    Reply
  •  
    Aug 22 02:43 PM
    Updated:
    BERN - $130 - "Roche offer substantially too low."
    source:
    seekingalpha.com/artic...
    BMO - $104
    source: news.moneycentral.msn....
    Citi raises target from $91 to $108
    CrossProfit $113/$118
    source:
    www.crossprofit.com/ar...
    JPM - $110 or higher..
    source: news.moneycentral.msn....
    LEH - $105
    MSCO - $110 is fair value.
    Rodman - $106 to $123
    source:
    www.bloggingstocks.com.../
    Oppenheimer & Co raised target from $88 to $105
    source: www.bloomberg.com/apps...
    RBC - $95 to $100 range.
    GSCO - regular $88 target withdrawn, advising party on deal.
    UBS - $115 to $135
    Reply
  •  
    Aug 23 03:12 PM
    Why would Art and the special committee entertain the buyout without waiting for the interim look at the adjuvant trial in November? That would be the absolutely fairest thing to do for the minority shareholders!
    Reply
More Comments on DNA ยป
More by Mike Huckman

Investment Resources
Money Management 

Research 

Seeking Alpha provides these ads as a service to its leading contributors
Articles on related themes
Mergers & Acquisitions 

Drug Manufacturers 

Biotech Diagnosis 

Biotech Equipment